Summary by Futu AI
Keejye Pharmaceutical-B (02171.HK) submitted a next-day disclosure report on June 25, 2024, disclosing its share buyback situation. According to the report, the company conducted several share buybacks through Hong Kong Exchanges and Clearing Limited (HKEx) between May 31 and June 25, 2024, with a total buyback of 3,985,500 shares, accounting for 0.692% of the issued shares. The latest buyback occurred on June 25, 2024, with a buyback of 145,500 shares at a price between HKD 4.9 and HKD 4.94 per share and a total payment of HKD 716,150. The company confirmed that all buybacks were carried out in accordance with relevant listing rules and legal regulations, and had obtained formal authorization from the board of directors. In addition, the company obtained authorization for share buybacks on May 21, 2024, and the total number of shares that can be repurchased is 57,564,391. According to regulations, the company will not conduct any new share issuance or inventory share resale or transfer within 30 days after completing share buybacks, and this suspension period will continue until July 25, 2024.